Compare Peloton Interactive Inc (PTON) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Recursion Pharmaceuticals Inc — how do they compare? Peloton Interactive Inc trades at $4.91 (market cap $2.13B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Peloton Interactive Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 8,365,857). Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PTON | RXRX | |
|---|---|---|
Market Cap | $2.13B | $2.31B |
Volume | 8,365,857 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $6.79 |
52-Week Low | $3.71 | $2.84 |
Typical Hold Time | 37 Days | 22 Days |
Enterprise Value | $2.64B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $4.92, up 1.03% for the day, as the company shows signs of operational improvement with positive operating cash flow of $333M in 2025. The stock remains in a bearish technical trend with negative shareholder equity of -$413.7M, though recent product launches including the foldable Tread Flex aim to broaden market appeal. Revenue declined to $2.49B in 2025 with a net loss of $118.9M, but profitability metrics show gradual improvement from previous years.
While PTON faces significant challenges including high debt levels and declining membership, the company achieved its first profitable year in 2026 with $63M net income. Analyst consensus remains cautiously optimistic with a $8.00 price target representing 63% upside potential. Key risks include execution of the turnaround strategy and competitive pressure in the connected fitness market.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
